Frovatriptan

Frovatriptan
Clinical data
Trade names	Frova
Other names	6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide; (6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
AHFS/Drugs.com	Monograph
MedlinePlus	a604013
Pregnancy; category	AU: B3 ; US: C (Risk not ruled out) ;
Routes of; administration	Oral
ATC code	N02CC07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	20–30%
Metabolism	Hepatic
Elimination half-life	26 hours
Excretion	Renal
Identifiers
	IUPAC name (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole;
CAS Number	158930-17-7 ;
PubChem CID	77992;
IUPHAR/BPS	7191;
DrugBank	DB00998 ;
ChemSpider	70378 ;
UNII	H82Q2D5WA7;
KEGG	D07997 ;
ChEMBL	ChEMBL1279 ;
CompTox Dashboard (EPA)	DTXSID0023080 ;
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.310 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3;
	InChI InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 ; Key:XPSQPHWEGNHMSK-SECBINFHSA-N ;
	(what is this?) (verify)

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]

Pharmacology

Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

Mechanism of action

Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT_1B/1D receptors. It has no significant effects on the GABA_A mediated channel activity and benzodiazepine binding sites.

Adverse effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Contraindications

Frovatriptan should not be given to patients with:

Ischemic heart disease
Cerebrovascular syndrome
Peripheral vascular disease
Uncontrolled hypertension
Hemiplegic or basilar migraine

US licensing

Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.[2]

gollark: Wait, does your language *support* comment syntax?

gollark: `[1 :: Int]` (Haskell), sort of thing?

gollark: ```zig var arena = std.heap.ArenaAllocator.init(std.heap.page_allocator); defer arena.deinit(); const alloc = &arena.allocator;```oh apio why

gollark: `const zero: T = 0; // I wish I were dead but this singlehandedly fixes the code`

gollark: Thus utilize Rüst, which has good döcs.

References

"Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
"Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.

External links

Frova (manufacturer's website)
Frovatriptan Succinate (patient information)
FDA labeling

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.

[2] "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.